Therefore, we next sought to determine the importance of the PI3K and MAPK downstream signaling pathways in lung cancer cells with mutant or wild-type EGFR using PI3K inhibitors and MEK inhibitors. This evidence concerns the gene MAP2K7 and lung cancer.